Company Overview of aTyr Pharma Inc.
aTyr Pharma Inc., a protein therapeutics company, engages in the discovery and development of biologic therapeutics based on physiocrines. It focuses on the discovery of phyisiocrines, which are a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in various physiologic settings; and the development of physiocrine-based medicines for indications in the areas of hematology, immune modulation, infection, and metabolism. The company’s lead product is Tmax, which is in preclinical development for thrombocytopenia. aTyr Pharma Inc. was incorporated in 2005 and is based in San Diego, California.
3565 General Atomics Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Executive Chairman and Chief Executive Officer
President and Chief Operating Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.
aTyr Pharma Inc. Key Developments
aTyr Pharma Appoints Fred Ramsdell as Vice President, Immunology
Nov 3 14
aTyr Pharma announced that Fred Ramsdell, Ph.D., joined aTyr as Vice President, Immunology. Prior to joining aTyr, Dr. Ramsdell helped establish the immunobiology research strategy for both Darwin Molecular and NovoNordisk. While at Celltech he led research efforts resulting in the discovery of Foxp3, a critical gene for normal immune function, the absence of which results in a rare but fatal autoimmunity in humans, and contributed to the identification and development of sclerostin, the target of a Phase III clinical program at Amgen/UCB.
aTyr Pharma Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:05 AM
Oct 27 14
aTyr Pharma Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:05 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: John Mendlein.
aTyr Pharma Inc. Appoints John C. Mckew as Vice President of Research
Oct 22 14
aTyr Pharma Inc. announced that John C. McKew, joined the company as vice president of research. Dr. McKew brings more than two decades of expertise in translational research, including key leadership positions at the National Institutes of Health, Wyeth Research and Genetics Institute Inc. (prior to its acquisition by Wyeth). Dr. McKew will lead the company's efforts to expand and translate its novel Physiocrine biology into meaningful therapeutics to treat rare, grave immune-driven disorders. Dr. McKew most recently served as the acting scientific director of the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health. His responsibilities included developing both the Therapeutics for Rare and Neglected Disease (TRND) and the Bridging Interventional Development Gaps (BrIDGs) programs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|